Emmanuel Katsanis

List of Publications by Year
in descending order

159	5,114	87888	106344
papers	citations	38 h-index	65 g-index

163	163	163	6410
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Editorial: Advances in Pediatric Hematopoietic Cell Therapies and Transplantation. Frontiers in Pediatrics, 2022, 10, 847288.	1.9	0
2	Recent COVID-19 vaccination has minimal effects on the physiological responses to graded exercise in physically active healthy people. Journal of Applied Physiology, 2022, 132, 275-282.	2.5	16
3	Hematopoietic Cell Transplantation for Congenital Dyserythropoietic Anemia: A Report from the Pediatric Transplant and Cellular Therapy Consortium. Transplantation and Cellular Therapy, 2022, , .	1.2	4
4	Salutary effects of moderate but not high intensity aerobic exercise training on the frequency of peripheral T-cells associated with immunosenescence in older women at high risk of breast cancer: a randomized controlled trial. Immunity and Ageing, 2022, 19, 17.	4.2	9
5	Commentary: Post-Transplantation Cyclophosphamide Uniquely Restrains Alloreactive CD4+ T-Cell Proliferation and Differentiation After Murine MHC-Haploidentical Hematopoietic Cell Transplantation. Frontiers in Immunology, 2022, 13, 887648.	4.8	3
6	Feasibility and efficacy of partially replacing post-transplant cyclophosphamide with bendamustine in pediatric and young adult patients undergoing haploidentical bone marrow transplantation. Transplantation and Cellular Therapy, 2022, , .	1.2	5
7	Concurrent application of blinatumomab and haploidentical donor leukocyte infusions for refractory primary mediastinal large B-cell lymphoma. Therapeutic Advances in Hematology, 2021, 12, 204062072199434.	2.5	2
8	Have CD19-directed immunotherapy and haploidentical hematopoietic cell transplantation transformed pediatric B-cell acute lymphoblastic leukemia into a chronic disease?. OncoImmunology, 2021, 10, 1956125.	4.6	0
9	Haploidentical hematopoietic cell transplantation is even more advantageous during the COVIDâ€19 pandemic. Pediatric Transplantation, 2021, 25, e14004.	1.0	1
10	Immunomodulatory Effects of Bendamustine in Hematopoietic Cell Transplantation. Cancers, 2021, 13, 1702.	3.7	9
11	Regulatory Dendritic Cells Induced by Bendamustine Are Associated With Enhanced Flt3 Expression and Alloreactive T-Cell Death. Frontiers in Immunology, 2021, 12, 699128.	4.8	10
12	Exercise and the immune system: taking steps to improve responses to cancer immunotherapy. , 2021, 9, e001872.		49
13	Voluntary Wheel Running Slows Tumor Progression In A Murine Lymphoma Model. Medicine and Science in Sports and Exercise, 2021, 53, 367-367.	0.4	0
14	Human Lymphocytes Mobilized With Exercise Extend Survival And Lower Leukemic Burden In Xenogeneic Mice. Medicine and Science in Sports and Exercise, 2021, 53, 367-367.	0.4	0
15	Acute Exercise Enhances The Ex Vivo Expansion And Cytolytic Phenotype Of Cytokine Induced Killer Cells. Medicine and Science in Sports and Exercise, 2021, 53, 366-366.	0.4	0
16	Exercise Enhances The Anti-leukemia Activity Of Expanded Î³Î´ T-cells Via DNAM-1 Upregulation And PVR/Nectin-2 Recognition. Medicine and Science in Sports and Exercise, 2021, 53, 365-366.	0.4	0
17	Outcomes of pediatric patients with therapy-related myeloid neoplasms. Bone Marrow Transplantation, 2021, 56, 2997-3007.	2.4	4
18	Acute exercise increases immune responses to SARS CoV-2 in a previously infected man. Brain, Behavior, & Immunity - Health, 2021, 18, 100343.	2.5	13

#	Article	IF	Citations
19	Recent Advances in Haploidentical Hematopoietic Cell Transplantation for Pediatric Hematologic Malignancies. , 2021, , 157-168.		0
20	Case Report: Haploidentical Bone Marrow Transplantation in Two Brothers With Wiskottâ€“Aldrich Syndrome Using Their Father as the Donor. Frontiers in Pediatrics, 2021, 9, 647505.	1.9	1
21	Improved Outcomes of Transplant Associated Thrombotic Microangiopathy with Early Initiation of Eculizumab. Biology of Blood and Marrow Transplantation, 2020, 26, S130.	2.0	0
22	Progressive substitution of posttransplant cyclophosphamide with bendamustine: A phase I study in haploidentical bone marrow transplantation. EJHaem, 2020, 1, 286-292.	1.0	12
23	Bendamustine Conditioning Skews Murine Host DCs Toward Pre-cDC1s and Reduces GvHD Independently of Batf3. Frontiers in Immunology, 2020, 11, 1410.	4.8	11
24	The effects of Î²1 and Î²1+2 adrenergic receptor blockade on the exercise-induced mobilization and ex vivo expansion of virus-specific T cells: implications for cellular therapy and the anti-viral immune effects of exercise. Cell Stress and Chaperones, 2020, 25, 993-1012.	2.9	5
25	Bendamustine with total body irradiation conditioning yields tolerant T-cells while preserving T-cell-dependent graft-versus-leukemia. OncoImmunology, 2020, 9, 1758011.	4.6	11
26	T-Cell Replete Myeloablative Haploidentical Bone Marrow Transplantation Is an Effective Option for Pediatric and Young Adult Patients With High-Risk Hematologic Malignancies. Frontiers in Pediatrics, 2020, 8, 282.	1.9	20
27	Exercise as a countermeasure for latent viral reactivation during long duration space flight. FASEB Journal, 2020, 34, 2869-2881.	0.5	23
28	The immunological case for staying active during the COVID-19 pandemic. Brain, Behavior, and Immunity, 2020, 87, 6-7.	4.1	123
29	Systemic Î² 1 -Adrenergic Receptor Blockade Augments NK-Cell Mobilization In Response To Acute Exercise In Humans. Medicine and Science in Sports and Exercise, 2020, 52, 16-16.	0.4	1
30	T-cell Response To Exercise Training Among Women At Heightened Risk Of Breast Cancer.. Medicine and Science in Sports and Exercise, 2020, 52, 665-665.	0.4	1
31	Hematopoietic Cell Transplantation for Congenital Dyserythropoietic Anemia: A Report from the Pediatric Transplant and Cellular Therapy Consortium (PTCTC). Blood, 2020, 136, 42-43.	1.4	0
32	Transfusion independence after repeated haploidentical hematopoietic cell transplants in a patient with congenital dyserythropoietic anemia type II and hemosiderosis. Pediatric Transplantation, 2019, 23, e13587.	1.0	1
33	Reduced Intensity Vs Myeloablative Conditioning Regimen for Pediatric Therapy-Related Myelodysplastic Syndrome/Acute Myeloid Leukemia. Biology of Blood and Marrow Transplantation, 2019, 25, S14-S15.	2.0	0
34	The Impact of Low-Dose Cranial Boost on the Long-Term Outcomes of Adult Patients with High-Risk Acute Lymphoblastic Leukemia Undergoing Total Body Irradiation and Allogeneic Hematopoietic Stem Cell Transplantation. Practical Radiation Oncology, 2019, 9, e283-e289.	2.1	9
35	A Phase I Study of Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide and/or Bendamustine. Biology of Blood and Marrow Transplantation, 2019, 25, S224.	2.0	1
36	Esophageal Varices in Adolescent and Young Adult Males with Acute Lymphocytic Leukemia. Journal of Adolescent and Young Adult Oncology, 2019, 8, 217-220.	1.3	0

#	Article	IF	Citations
37	Bendamustine with Total Body Irradiation Limits Murine Graft-versus-Host Disease in Part Through Effects on Myeloid-Derived Suppressor Cells. Biology of Blood and Marrow Transplantation, 2019, 25, 405-416.	2.0	13
38	Systemic Î²-Adrenergic Receptor Activation Augments the ex vivo Expansion and Anti-Tumor Activity of Vγ9Vδ2 T-Cells. Frontiers in Immunology, 2019, 10, 3082.	4.8	36
39	Successful resolution of hyperammonemia following hematopoietic cell transplantation with directed treatment of Ureaplasma parvum infection. Transplant Infectious Disease, 2018, 20, e12839.	1.7	27
40	Allogeneic haematopoietic cell transplantation for extranodal natural killer/Tâ€cell lymphoma, nasal type: a <scp>CIBMTR</scp> analysis. British Journal of Haematology, 2018, 182, 916-920.	2.5	59
41	Supernumerary Incisors in CB6F1 Mice Conditioned with Chemotherapy and Total Body Irradiation before Bone Marrow Transplantation. Comparative Medicine, 2018, 68, 349-352.	1.0	0
42	Long-Term Outcomes of Adult Patients with High-Risk Acute Lymphoblastic Leukemia Undergoing Total Body Irradiation with or without Whole Brain Boost. International Journal of Radiation Oncology Biology Physics, 2018, 102, e253.	0.8	0
43	Î²2-Adrenergic receptor signaling mediates the preferential mobilization of differentiated subsets of CD8+ T-cells, NK-cells and non-classical monocytes in response to acute exercise in humans. Brain, Behavior, and Immunity, 2018, 74, 143-153.	4.1	80
44	Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide/Bendamustine in Pediatric and Young Adult Patients with Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 2018, 24, 2034-2039.	2.0	32
45	The Comparison of Unmanipulated Bone Marrow Versus Peripheral Blood Haploidentical Stem Cell Transplantation in Adult Acute Leukemia: A Systematic Review and Meta-Analysis. Blood, 2018, 132, 5768-5768.	1.4	2
46	Bendamustine with Total Body Irradiation Limits Murine Graft-Versus-Host Disease in Part Via Myeloid-Derived Suppressor Cells. Blood, 2018, 132, 2040-2040.	1.4	2
47	Bendamustine Conditioning Alters Host Dendritic Cell Composition and Function. Blood, 2018, 132, 5670-5670.	1.4	0
48	Outcomes of T-Cell Depleted Haploidentical Peripheral Blood Stem Cell Transplantation for Adult Acute Leukemia: A Meta-Analysis. Blood, 2018, 132, 5779-5779.	1.4	0
49	Potential niche indications for blinatumomab as a bridge to hematopoietic cell transplantation. Bone Marrow Transplantation, 2017, 52, 1671-1673.	2.4	6
50	Pak2 regulates myeloid-derived suppressor cell development in mice. Blood Advances, 2017, 1, 1923-1933.	5.2	13
51	Allogeneic Transplant in ELANE and MEFV Mutation Positive Severe Cyclic Neutropenia: Review of Prognostic Factors for Secondary Severe Events. Case Reports in Hematology, 2017, 2017, 1-7.	0.4	4
52	Postâ€transplant bendamustine reduces Gv<scp>HD</scp> while preserving GvL in experimental haploidentical bone marrow transplantation. British Journal of Haematology, 2016, 174, 102-116.	2.5	27
53	Treatment of Pediatric CNS Leukemia With Cranial or Craniospinal Boost in Conjunction With Total Body Irradiation as Part of the Conditioning Regimen for Bone Marrow Transplantation. International Journal of Radiation Oncology Biology Physics, 2016, 96, S166.	0.8	1
54	Alternative Donor Hematopoietic Cell Transplantation Conditioned With Myeloablative Busulfan, Fludarabine, and Melphalan is Well Tolerated and Effective Against High-risk Myeloid Malignancies. Journal of Pediatric Hematology/Oncology, 2016, 38, e315-e318.	0.6	11

#	Article	IF	Citations
55	Targeted immunotherapy for pediatric solid tumors. OncoImmunology, 2016, 5, e1087637.	4.6	9
56	Factors associated with improved outcomes after second allogeneic hematopoietic cell transplantation for relapsed pediatric leukemia. Annals of Hematology, 2016, 95, 637-644.	1.8	13
57	Pak2 Regulates MDSC Development and Function. Blood, 2016, 128, 705-705.	1.4	0
58	Extramedullary Breast Relapse of Acute Lymphoblastic Leukemia Controlled with a Second Allogeneic/Autologous Hematopoietic Cell Transplant. Journal of Adolescent and Young Adult Oncology, 2015, 4, 50-53.	1.3	4
59	Pediatric secondary chronic myeloid leukemia following cardiac transplantation for anthracyclineâ€induced cardiomyopathy. Pediatric Blood and Cancer, 2015, 62, 166-168.	1.5	9
60	T Lymphocyte Inhibition by Tumor-Infiltrating Dendritic Cells Involves Ectonucleotidase CD39 but Not Arginase-1. BioMed Research International, 2015, 2015, 1-10.	1.9	5
61	Neuroblastomaâ˜†. , 2015, , .		0
62	Endoplasmic Reticulum Chaperones and Their Roles in the Immunogenicity of Cancer Vaccines. Frontiers in Oncology, 2015, 4, 379.	2.8	13
63	The complex pathophysiology of acquired aplastic anaemia. Clinical and Experimental Immunology, 2015, 180, 361-370.	2.6	106
64	Immunotherapy for Pediatric Solid Tumors. , 2015, , 47-67.		0
65	Chemotherapeutic targeting of myeloid-derived suppressor cells. OncoImmunology, 2014, 3, e27359.	4.6	11
66	Activated MHC-mismatched T helper-1 lymphocyte infusion enhances GvL with limited GvHD. Bone Marrow Transplantation, 2014, 49, 1076-1083.	2.4	14
67	Treatment of Hepatoblastoma With High-dose Chemotherapy and Stem Cell Rescue. Journal of Pediatric Hematology/Oncology, 2014, 36, 362-368.	0.6	10
68	Doxorubicin Eliminates Myeloid-Derived Suppressor Cells and Enhances the Efficacy of Adoptive T-Cell Transfer in Breast Cancer. Cancer Research, 2014, 74, 104-118.	0.9	319
69	<scp>PIAS</scp>1 and <scp>STAT</scp>â€3 impair the tumoricidal potential of <scp>IFN</scp>â€Îłâ€stimulated mouse dendritic cells generated with <scp>IL</scp>â€15. European Journal of Immunology, 2014, 44, 2489-2499.	2.9	7
70	Outcomes after Hematopoietic Stem Cell Transplantation for Children with I-Cell Disease. Biology of Blood and Marrow Transplantation, 2014, 20, 1847-1851.	2.0	150
71	Abstract 150: Role of reactive oxygen species in doxorubicin-induced apoptosis of myeloid-derived suppressor cells. , 2014, , .		0
72	The â€˜peptidomeâ€™ of tumour-derived chaperone-rich cell lysate anti-cancer vaccines reveals potential tumour antigens that stimulate tumour immunity. International Journal of Hyperthermia, 2013, 29, 380-389.	2.5	13

#	Article	IF	Citations
73	Prolonged remission of advanced bronchoalveolar adenocarcinoma in a dog treated with autologous, tumour-derived chaperone-rich cell lysate (CRCL) vaccine. International Journal of Hyperthermia, 2013, 29, 390-398.	2.5	15
74	The Multifaceted Role of Th17 Lymphocytes and Their Associated Cytokines in Cancer. Clinical and Developmental Immunology, 2013, 2013, 1-11.	3.3	33
75	Dendritic Cell Tumor Killing Activity and Its Potential Applications in Cancer Immunotherapy. Critical Reviews in Immunology, 2013, 33, 1-21.	0.5	38
76	Dendritic Cells for Cancer Immunotherapy. , 2013, , 251-270.		0
77	Abstract 4740: Doxorubicin eliminates tumor-induced myeloid-derived suppressor cells and enhances T-helper lymphocyte-based immunotherapy in a murine breast cancer model.. , 2013, , .		0
78	Cytotoxic and antigen presenting functions of T helper-1-activated dendritic cells. OncoImmunology, 2012, 1, 566-568.	4.6	6
79	Diagnostic and Treatment Challenges for the Pediatric Hematologist Oncologist in Endemic Areas for Coccidioidomycosis. Journal of Pediatric Hematology/Oncology, 2012, 34, 389-394.	0.6	8
80	Myeloid-derived suppressor cells from tumor-bearing mice impair TGF-Î²-induced differentiation of CD4+CD25+FoxP3+ Tregs from CD4+CD25â^'FoxP3â^' T cells. Journal of Leukocyte Biology, 2012, 92, 987-997.	3.3	84
81	Late Effects in Adult Survivors of Pediatric Cancer: A Guide for the Primary Care Physician. American Journal of Medicine, 2012, 125, 636-641.	1.5	44
82	Nebulized Interleukin 2 Liposomes: Aerosol Characteristics and Biodistribution. Journal of Pharmacy and Pharmacology, 2011, 49, 960-971.	2.4	37
83	Th-1 Lymphocytes Induce Dendritic Cell Tumor Killing Activity by an IFN-Î³â€“Dependent Mechanism. Journal of Immunology, 2011, 187, 6310-6317.	0.8	33
84	Immunologic effects of rituximab on the human spleen in immune thrombocytopenia. Blood, 2011, 118, 4394-4400.	1.4	98
85	Allogeneic effector/memory Th-1 cells impair FoxP3+ regulatory T lymphocytes and synergize with chaperone-rich cell lysate vaccine to treat leukemia. Blood, 2011, 117, 1555-1564.	1.4	19
86	Cytotoxic Dendritic Cells Generated from Cancer Patients. Journal of Immunology, 2011, 187, 2775-2782.	0.8	23
87	The Dendritic Cell-Regulatory T Lymphocyte Crosstalk Contributes to Tumor-Induced Tolerance. Clinical and Developmental Immunology, 2011, 2011, 1-14.	3.3	75
88	Killer dendritic cells and their potential for cancer immunotherapy. Cancer Immunology, Immunotherapy, 2010, 59, 1-11.	4.2	44
89	Peroxynitrite-Dependent Killing of Cancer Cells and Presentation of Released Tumor Antigens by Activated Dendritic Cells. Journal of Immunology, 2010, 184, 1876-1884.	0.8	58
90	Personalized dendritic cell-based tumor immunotherapy. Immunotherapy, 2010, 2, 57-68.	2.0	55

#	Article	IF	Citations
91	Signaling pathways induced by a tumor-derived vaccine in antigen presenting cells. Immunobiology, 2010, 215, 535-544.	1.9	7
92	236: Busulfan and Single-Dose Melphalan as Preparative Therapy for Infants and Young Children Undergoing Stem Cell Transplantation for Leukemia: A Single Center Experience. Biology of Blood and Marrow Transplantation, 2008, 14, 87-88.	2.0	1
93	Differential capacity of chaperone-rich lysates in cross-presenting human endogenous and exogenous melanoma differentiation antigens. International Journal of Hyperthermia, 2008, 24, 623-637.	2.5	9
94	Imatinib Mesylate Inhibits CD4+CD25+ Regulatory T Cell Activity and Enhances Active Immunotherapy against BCR-ABLâ˜' Tumors. Journal of Immunology, 2008, 181, 6955-6963.	0.8	140
95	Chaperone-rich tumor cell lysate-mediated activation of antigen-presenting cells resists regulatory T cell suppression. Journal of Leukocyte Biology, 2008, 83, 1049-1059.	3.3	24
96	A chaperone protein-enriched tumor cell lysate vaccine generates protective humoral immunity in a mouse breast cancer model. Molecular Cancer Therapeutics, 2008, 7, 721-729.	4.1	10
97	Chaperoneâ€rich cell lysate embedded with BCRâ€ABL peptide demonstrates enhanced antiâ€tumor activity against a murine BCRâ€ABL positive leukemia. FASEB Journal, 2007, 21, 2173-2184.	0.5	13
98	Human ovarian tumour-derived chaperone-rich cell lysate (CRCL) elicits T cell responses in vitro. Clinical and Experimental Immunology, 2007, 148, 136-145.	2.6	21
99	CD4+CD25+FoxP3+ regulatory T cells suppress Mycobacterium tuberculosis immunity in patients with active disease. Clinical Immunology, 2007, 123, 50-59.	3.2	241
100	The inhibition of TNF-Î± anti-tumoral properties by blocking antibodies promotes tumor growth in a rat model. Experimental Cell Research, 2007, 313, 2345-2355.	2.6	35
101	Peritransplantation Vaccination with Chaperone-Rich Cell Lysate Induces Antileukemia Immunity. Biology of Blood and Marrow Transplantation, 2006, 12, 275-283.	2.0	9
102	Apoptotic, necrotic, or fused tumor cells: An equivalent source of antigen for dendritic cell loading. Apoptosis: an International Journal on Programmed Cell Death, 2006, 11, 1513-1524.	4.9	36
103	Vesiculated alpha-tocopheryl succinate enhances the anti-tumor effect of dendritic cell vaccines. Cancer Immunology, Immunotherapy, 2006, 55, 166-177.	4.2	23
104	Chaperone-rich cell lysates, immune activation and tumor vaccination. Cancer Immunology, Immunotherapy, 2006, 55, 329-338.	4.2	38
105	Tumor-derived CD4+CD25+ regulatory T cell suppression of dendritic cell function involves TGF-Î² and IL-10. Cancer Immunology, Immunotherapy, 2006, 56, 48-59.	4.2	190
106	Natural killer cells play a key role in the antitumor immunity generated by chaperone-rich cell lysate vaccination. International Journal of Cancer, 2006, 119, 2624-2631.	5.1	32
107	Induction of BCR-ABLâ€"specific immunity following vaccination with chaperone-rich cell lysates derived from BCR-ABL+ tumor cells. Blood, 2005, 105, 2016-2022.	1.4	36
108	Evidence for a Novel, Caspase-8-Independent, Fas Death Domain-Mediated Apoptotic Pathway. Journal of Biomedicine and Biotechnology, 2004, 2004, 41-51.	3.0	18

#	Article	IF	Citations
109	Cargo from Tumor-Expressed Albumin Inhibits T-Cell Activation and Responses. Cancer Research, 2004, 64, 8085-8092.	0.9	20
110	Imatinib mesylate effectively combines with chaperone-rich cell lysate-loaded dendritic cells to treatbcr-abl+ murine leukemia. International Journal of Cancer, 2004, 110, 251-259.	5.1	30
111	Chaperone Proteins/Heat Shock Proteins As Anticancer Vaccines. , 2004, , 297-316.		0
112	Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers. Cancer Immunology, Immunotherapy, 2003, 52, 226-234.	4.2	74
113	Exogenous stress proteins enhance the immunogenicity of apoptotic tumor cells and stimulate antitumor immunity. Blood, 2003, 101, 245-252.	1.4	97
114	Tumor-derived, chaperone-rich cell lysate activates dendritic cells and elicits potent antitumor immunity. Blood, 2003, 101, 4485-4491.	1.4	77
115	Stressed apoptotic tumor cells stimulate dendritic cells and induce specific cytotoxic T cells. Blood, 2002, 100, 4108-4115.	1.4	150
116	Stressed apoptotic tumor cells express heat shock proteins and elicit tumor-specific immunity. Blood, 2001, 97, 3505-3512.	1.4	145
117	Dendritic-cell-peptide immunization provides immunoprotection against bcr-ablâ€Š-positive leukemia in mice. Cancer Immunology, Immunotherapy, 2001, 50, 31-40.	4.2	43
118	Invasion and metastasis of a mammary tumor involves TGF-? signaling. International Journal of Cancer, 2001, 91, 76-82.	5.1	148
119	Tumor-derived multiple chaperone enrichment by free-solution isoelectric focusing yields potent antitumor vaccines. Cancer Immunology, Immunotherapy, 2000, 49, 476-484.	4.2	50
120	Effects of Geldanamycin, a Heat-Shock Protein 90-Binding Agent, on T Cell Function and T Cell Nonreceptor Protein Tyrosine Kinases. Journal of Immunology, 2000, 164, 2915-2923.	0.8	50
121	Immunoprotective activities of multiple chaperone proteins isolated from murine B-cell leukemia/lymphoma. Clinical Cancer Research, 2000, 6, 909-15.	7.0	49
122	Autologous stem cell transplantation for high-risk pediatric solid tumors. Bone Marrow Transplantation, 1999, 24, 609-615.	2.4	36
123	Activated peripheral blood mononuclear cells from patients receiving subcutaneous interleukin-2 following autologous stem cell transplantation prolong survival of SCID mice bearing human lymphoma. Bone Marrow Transplantation, 1998, 22, 185-191.	2.4	4
124	Molecular chaperones: biology and prospects for pharmacological intervention. Pharmacological Reviews, 1998, 50, 493-514.	16.0	140
125	Patterns of Hepatic and Splenic Colonization by an Attenuated Strain of Salmonella typhimurium Containing the Gene for Human Interleukin-2: A Novel Anti-Tumor Agent. Cancer Biotherapy and Radiopharmaceuticals, 1997, 12, 37-45.	1.0	23
126	Improved Immunostimulatory Function of Bone Marrow Derived Macrophages Transduced with the Granulocyte-Macrophage Colony Stimulating Factor Gene. Cancer Biotherapy and Radiopharmaceuticals, 1997, 12, 27-36.	1.0	1

#	Article	IF	Citations
127	Antitumor mechanisms of attenuated Salmonella typhimurium containing the gene for human interleukin-2: A novel antitumor agent?. Journal of Pediatric Surgery, 1997, 32, 301-306.	1.6	57
128	Unrelated donor bone marrow transplantation for children with acute leukemia.. Journal of Clinical Oncology, 1997, 15, 557-565.	1.6	95
129	Unrelated donor bone marrow transplantation for children and adolescents with aplastic anaemia or myelodysplasia. British Journal of Haematology, 1997, 96, 749-756.	2.5	72
130	Interleukin-2 liposome inhalation therapy is safe and effective for dogs with spontaneous pulmonary metastases. Cancer, 1997, 79, 1409-1421.	4.1	108
131	The role of B7 costimulation by murine acute myeloid leukemia in the generation and function of a CD8+ T-cell line with potent in vivo graft-versus-leukemia properties. Blood, 1997, 89, 3477-85.	1.4	13
132	Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity. Biology of Blood and Marrow Transplantation, 1997, 3, 34-44.	2.0	65
133	Interleukin-2 Secretion by Transduced and Unselected BDL-2 Lymphoma Results in Increased Survival in Mice with Previously Established Disseminated Disease. Cancer Biotherapy and Radiopharmaceuticals, 1996, 11, 155-164.	1.0	0
134	Effective Immunization Against Neuroblastoma Using Double-Transduced Tumor Cells Secreting GM-CSF and Interferon-Î³. Journal of Immunotherapy, 1996, 19, 113-124.	2.4	22
135	IL-15 ADMINISTRATION FOLLOWING SYNGENEIC BONE MARROW TRANSPLANTATION PROLONGS SURVIVAL OF LYMPHOMA BEARING MICE1. Transplantation, 1996, 62, 872-875.	1.0	25
136	Irradiation of singly and doubly transduced murine neuroblastoma cells expressing B7-1 and producing interferon-gamma reduces their capacity to induce systemic immunity. Cancer Gene Therapy, 1996, 3, 75-82.	4.6	11
137	B7-1 expression decreases tumorigenicity and induces partial systemic immunity to murine neuroblastoma deficient in major histocompatibility complex and costimulatory molecules. Cancer Gene Therapy, 1995, 2, 39-46.	4.6	12
138	Interleukin-1 alpha administered after autologous transplantation: a phase I/II clinical trial. Blood, 1994, 84, 2044-2049.	1.4	36
139	Interleukin-2 Gene Transfer into Murine Neuroblastoma Decreases Tumorigenicity and Enhances Systemic Immunity Causing Regression of Preestablished Retroperitoneal Tumors. Journal of Immunotherapy, 1994, 15, 81-90.	2.4	30
140	Transfection of the mouse ICAM-1 gene into murine neuroblastoma enhances susceptibility to lysis, reduces in vivo tumorigenicity and decreases ICAM-2-dependent killing. Cancer Immunology, Immunotherapy, 1994, 38, 135-141.	4.2	17
141	Infusions of interleukin-1? after autologous transplantation for Hodgkin's disease and non-Hodgkin's lymphoma induce effector cells with antilymphoma cytolytic activity. Journal of Clinical Immunology, 1994, 14, 205-211.	3.8	8
142	Retroperitoneal inoculation of murine neuroblastoma results in a reliable model for evaluation of the antitumor immune response. Journal of Pediatric Surgery, 1994, 29, 538-542.	1.6	13
143	Transfection of the mouse ICAM-1 gene into murine neuroblastoma enhances susceptibility to lysis, reduces in vivo tumorigenicity and decreases ICAM-2-dependent killing. Cancer Immunology, Immunotherapy, 1994, 38, 135-141.	4.2	2
144	Interleukin-1 alpha administered after autologous transplantation: a phase I/II clinical trial. Blood, 1994, 84, 2044-2049.	1.4	12

#	Article	IF	Citations
145	Short-term ex vivo activation of splenocytes with anti-CD3 plus IL-2 and infusion post-BMT into mice results in in vivo expansion of effector cells with potent anti-lymphoma activity. Bone Marrow Transplantation, 1994, 14, 563-72.	2.4	6
146	Depot Characteristics and Biodistribution of Interleukin-2 Liposomes, Importance of Route of Administration. Journal of Immunotherapy, 1992, 12, 3-31.	2.4	51
147	Proliferation and cytolytic function of anti-CD3 + interleukin-2 stimulated peripheral blood mononuclear cells following bone marrow transplantation. Blood, 1991, 78, 1286-1291.	1.4	17
148	Importance in timing of cyclophosphamide on the enhancement of interleukin-2-induced cytolysis. Cancer Immunology, Immunotherapy, 1991, 34, 74-78.	4.2	11
149	Proliferation and cytolytic function of anti-CD3 + interleukin-2 stimulated peripheral blood mononuclear cells following bone marrow transplantation. Blood, 1991, 78, 1286-1291.	1.4	1
150	Anti-tumor vaccine adjuvant effects of IL-2 liposomes in mice immunized against MCA-102 sarcoma. European Cytokine Network, 1991, 2, 311-8.	2.0	13
151	Antitumor effects of interleukin 2 liposomes and anti-CD3-stimulated T-cells against murine MCA-38 hepatic metastasis. Cancer Research, 1991, 51, 2127-32.	0.9	40
152	Proliferation and cytolytic function of anti-CD3 + interleukin-2 stimulated peripheral blood mononuclear cells following bone marrow transplantation. Blood, 1991, 78, 1286-91.	1.4	6
153	Increased local antitumor effects of interleukin 2 liposomes in mice with MCA-106 sarcoma pulmonary metastases. Cancer Research, 1990, 50, 1853-6.	0.9	48
154	Thyroid dysfunction following bone marrow transplantation: long-term follow-up of 80 pediatric patients. Bone Marrow Transplantation, 1990, 5, 335-40.	2.4	57
155	Influenza in children with cancer. Journal of Pediatrics, 1989, 115, 33-39.	1.8	119
156	Treatment of acquired severe aplastic anemia. The American Journal of Pediatric Hematology/oncology, 1989, 11, 360-7.	1.3	5
157	Prevalence and significance of mild bleeding disorders in children with recurrent epistaxis. Journal of Pediatrics, 1988, 113, 73-76.	1.8	66
158	Systemic lupus erythematosus and sickle hemoglobinopathies: A report of two cases and review of the literature. American Journal of Hematology, 1987, 25, 211-214.	4.1	31
159	Neutrophilic eccrine hidradenitis in acute myelomonocytic leukemia. The American Journal of Pediatric Hematology/oncology, 1987, 9, 204-8.	1.3	13